Imipridones ONC201 and ONC206 reduce expression of neogenin and EZH1/2 which correlate with synergy following their combination with EZH1/2 or HDAC inhibitors in treatment of DMG and other tumors

被引：0

|

作者：

Zhang, Yiqun

El-Deiry, Wafik S.

机构：

来源：

CANCER RESEARCH | 2023年 / 83卷 / 07期

关键词：

D O I：

10.1158/1538-7445.AM2023-2671

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2671

引用

收藏

页数：2

相关论文

共 3 条

[1] SYNERGISTIC TUMOR SUPPRESSION FROM COMBINATION OF ONC201 AND EPIGENETIC MODULATORS EZH2 OR HDAC INHIBITOR PROVIDES A NOVEL TREATMENT STRATEGY FOR GBM AND DMG
Zhang, Yiqun
Zhou, Lanlan
Howard, Safran
Seyhan, Attila
El-Deiry, Wafik
NEURO-ONCOLOGY, 2020, 22 : 64 - 65
[2] Potent synergistic tumor cell suppression from combination of ONC201 and epigenetic modulators EZH2 or HDAC inhibitors provides a novel treatment strategy for solid tumors
Zhang, Yiqun
Zhou, Lanlan
Glantz, Michael
Safran, Howard
Seyhan, Attila
El-Deiry, Wafik S.
CANCER RESEARCH, 2020, 80 (16)
[3] PARP inhibitor rucaparib in combination with imipridones ONC201 or ONC212 demonstrates preclinical synergy against BRCA1/2-deficient breast, ovarian, and prostate cancer cells
Ghandali, Maryam
Huntington, Kelsey E.
Srinivasan, Praveen
Dizon, Don S.
Graff, Stephanie L.
Carneiro, Benedito A.
El-Deiry, Wafik S.
CANCER RESEARCH, 2023, 83 (07)